Background/Objectives: Hodgkin lymphoma (HL) is the most common hematological malignancy among women of reproductive age. However, data on disease outcomes and infectious complications in pregnancy-associated HL are limited. No prior study has examined patients treated exclusively in the postpartum period. Our objective was to assess whether pregnancy-associated HL is associated with poorer disease outcomes and an increased risk of infectious complications. Methods: A multicenter, retrospective matched cohort study included 13 women diagnosed with HL during pregnancy or within 12 months postpartum (pregnancy-associated, PA) and 22 matched non-pregnancy-associated (NPA) controls. Controls were matched by International Prognostic Score, Ann Arbor stage, and age (within ±5 years), with diagnoses made between 2016 and 2025. Conditional logistic regression and mixed-effects Poisson regression were used to analyze infectious episodes separately for first-line and subsequent treatments. Progression-free survival (PFS) was estimated using the Kaplan–Meier method. Results: During first-line therapy, the PA group demonstrated significantly higher odds of any infection (OR 5.47, 95% CI 1.11–26.88, p = 0.037) and a higher number of infectious episodes (IRR 3.11, 95% CI 1.73–5.62, p < 0.001). No statistically significant differences were observed during subsequent lines of treatment. Progressive disease following first-line therapy was more frequent in the PA group (38.5% vs. 9.1%, p = 0.0559). Progression-free survival (PFS) at 12 months was 52.7% (95% CI 19.0–78.2) in the PA group compared to 77.3% (95% CI 53.7–89.8) in the NPA group (log-rank p = 0.27). No deaths were reported in either group. Conclusions: Pregnancy-associated HL is linked to a higher risk of infectious complications during first-line treatment and an increased rate of primary progression. These findings support the need for closer infectious surveillance in this population and should be confirmed in larger cohorts.